AUTHORS
Kunzangla Bhutia, Joachim Wolff, PhD2, Sarah Masser3, Dorian Dragicevic4, Imaz Khalid5, Florian Perner, MD6, Chun-Wei Chen, PhD7, Ashok Kumar Jayavelu Jr, PhD8, Florian H. Heidel IV, MD9, Tina M. Schnoeder10
AFFILIATIONS
1 Hannover Medical School, Hannover, Lower Saxony, Germany
2 Hannover Medical School, Hannover, Lower Saxony, Germany
3 German Cancer Research Center (DKFZ), Heidelberg, Germany
4 German Cancer Research Center (DKFZ), Heidelberg, Germany
5 Hannover Medical School, Hannover, Lower Saxony, Germany
6 Hannover Medical School, Hannover, Lower Saxony, Germany
7 Mayo Clinic, Rochester, United States
8 German Cancer Research Center (DKFZ), Heidelberg, Germany
9 Hannover Medical School, Hannover, Lower Saxony, Germany
10 Hannover Medical School, Hannover, Lower Saxony, Germany
ABSTRACT
The t(8;21)(q22;q22) translocation generates the RUNX1::RUNX1T1 (AML1-ETO; AE) fusion oncoprotein, a founding lesion in AML that reprograms hematopoietic transcriptional networks to enforce leukemic stem cell (LSC) self-renewal and maintenance. We recently identified the receptor tyrosine kinase effector phospholipase C gamma 1 (PLCG1) as a direct transcriptional target of AE and showed that PLCG1 is indispensable for LSC proliferation, self-renewal, and leukemia maintenance in vivo. However, the signaling mechanisms by which PLCG1 sustains leukemic transformation, and the structural features governing its function, remain undefined. Here, we dissect the signaling landscape and structural determinants underlying PLCG1 dependency in AE+ AML.
To map PLCG1-dependent signaling, we generated isogenic endogenous PLCG1 knockout (KO) and wildtype (WT) Kasumi-1 cells by CRISPR/Cas9 ribonucleoprotein-mediated genome editing. Loss of PLCG1 significantly impaired leukemic cell proliferation by 55% compared with WT controls (p=0.0011). Similarly, PLCG1 deficiency markedly reduced clonogenic potential (mean colonies WT: 189.2 vs. KO: 82.7; p=0.0003).
Quantitative phosphoproteomic profiling of PLCG1-KO and WT Kasumi-1 cells quantified 17,651 unique phosphorylation sites spanning 3,599 proteins. Of these, 9,411 phosphosites exhibited substantial regulation (abs(log2(FC))≥0.5) between genotypes. Within this, 291 phosphosites were significantly altered (FDR adjusted p-value≤ 0.05) in PLCG1-deficient cells. Pathway analysis highlighted alteration of cKIT-SOS-dependent downstream effectors including PI3K/AKT and MAPK signaling pathways. Flow cytometric analysis of 12 AML cell lines identified Kasumi-1 as cKIT high expressing cell line (p<0.0001). Consistent with these findings, immunoblot analysis validated increased KIT-abundance and phospho-cKIT (Tyr703) levels compared to other AML cell lines. Stimulation with stem cell factor (SCF) induced rapid phosphorylation of cKIT, PLCG1, AKT, and ERK, consistent with activation of the canonical cKIT signaling cascade. Pharmacologic inhibition of cKIT-signaling using imatinib (IC₅₀=2.7 μM) or dasatinib (IC₅₀=5.1 nM) suppressed Kasumi-1 cell proliferation in a dose-dependent manner. Imatinib reduced cell growth by 71% at 1.25 μM (p=0.0010) and by 86% at 2.5 μM (p=0.0008), whereas dasatinib decreased proliferation by 51% at 2.5 nM (p=0.0012) and by 69% at 5 nM (p=0.0001) compared with DMSO-controls. Notably, SCF stimulation partially restored inhibitor-suppressed signaling, confirming cKIT-dependent activation of PLCG1. To determine whether PLCG1 loss enhances sensitivity to cKIT inhibition, WT and PLCG1 KO Kasumi-1 cells were treated with dasatinib. Comparable reductions in cell growth were observed in both genotypes (WT: 46% at 2.5 nM, p=0.0003; 63% at 5 nM, p=0.0037; KO: 38% at 2.5 nM, p=0.0293; 58% at 5 nM, p=0.0025), indicating that PLCG1 deficiency does not further sensitize AE leukemia cells to pharmacologic cKIT inhibition. Thus, PLCG1 is primarily activated downstream of growth factor stimulation through KIT-dependent signaling pathways with partial redundancy following KIT-inhibition.
To identify functionally essential PLCG1 domains, we performed a CRISPR/Cas9 domain-targeting screen comprising 722 sgRNAs spanning the entire PLCG1 coding sequence, including non-targeting controls and sgRNAs targeting essential genes. The screen was conducted in AE-positive Kasumi-1 and SKNO-1 cells over 21 days. Selectively, two discrete regions centered around amino acid residues 534 and 838 were consistently depleted across four biological replicates in both cell lines, suggesting the presence of structurally critical functional domains.
To further resolve these candidate regions, we performed a targeted CRISPR base-editing screen covering amino acid residues flanking both hotspots. The highest-scoring candidate substitutions included Glu532Lys, Glu533Gly, Asp832Gly and Gly831Lys/Asp832Asn, which are currently being analyzed regarding functional consequences and cell signaling events.
Collectively, these findings define the cKIT-PLCG1 axis as a key signaling dependency in AE+ AML and uncover two previously uncharacterized, functionally essential regions of PLCG1. Together, they provide new mechanistic insight into how growth factor-driven cKIT signaling is relayed through PLCG1, and nominate its essential domains as structural vulnerabilities for therapeutic targeting in RUNX1::RUNX1T1-driven leukemia.
DISCLOSURES
Kunzangla Bhutia: No relevant conflicts of interest to declare.